Cost-effectiveness of an HPV self-collection campaign in Uganda: Comparing models for delivery of cervical cancer screening in a low-income setting

Health Policy and Planning

Volumn 32, Issue 7, 2017, Pages 956-968

  Campos, Nicole G ^a   Tsu, Vivien ^b   Jeronimo, Jose ^b   Njama Meya, Denise ^c   Mvundura, Mercy ^b   Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b PATH   (United States)

^c PATH   (Uganda)

Author keywords

Cancer; cervical screening; cost effectiveness analysis; decision making; women's health

Indexed keywords

ADULT; COLPOSCOPY; COST BENEFIT ANALYSIS; CRYOSURGERY; EARLY CANCER DIAGNOSIS; ECONOMICS; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; MASS SCREENING; MIDDLE AGED; MONTE CARLO METHOD; PROCEDURES; UGANDA; UTERINE CERVIX TUMOR;

ADULT; COLPOSCOPY; COST-BENEFIT ANALYSIS; CRYOSURGERY; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MASS SCREENING; MIDDLE AGED; MONTE CARLO METHOD; UGANDA; UTERINE CERVICAL NEOPLASMS;

EID: 85034567951     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czw182     Document Type: Article

References (49)

1. Arbyn M, Castle PE. 2015. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiology, Biomarkers and Prevention 24: 769-72.
2. Arbyn M, Verdoodt F, Snijders PJ et al. 2014. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: A meta-Analysis. The Lancet Oncology 15: 172-83.
3. Arrossi S, Thouyaret L, Herrero R et al. 2015. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): A population-based clusterrandomised trial. The Lancet Global Health 3: e85-94.
4. Bansil P, Wittet S, Lim JL et al. 2014. Acceptability of self-collection sampling for HPV-DNA testing in low-resource settings: A mixed methods approach. BMC Public Health 14: 596.
5. Campos NG, Burger EA, Sy S et al. 2014. An updated natural history model of cervical cancer: derivation of model parameters. American Journal of Epidemiology 180: 545-55.
6. Campos NG, Kim JJ, Castle PE et al. 2012. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. International Journal of Cancer 130: 2672-84.
7. Campos NG, Maza M, Alfaro K et al. 2015a. The comparative and costeffectiveness of HPV-based cervical cancer screening algorithms in El Salvador. International Journal of Cancer 15, 893-902.
8. Campos NG, Tsu V, Jeronimo J et al. 2015b. When and how often to screen for cervical cancer in three low-And middle-income countries: A costeffectiveness analysis. Papillomavirus Research 1, 38-58.
9. Castle PE, Rausa A, Walls T et al. 2011. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Preventive Medicine 52: 452-5.
10. Chirenje ZM, Rusakaniko S, Kirumbi L et al. 2001. Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries. BullWorld Health Organ 79: 127-132.
11. Ferlay J, Soerjomataram I, Ervik M et al. 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer.
12. Gavi, the Vaccine Alliance. 2014. 1.5 million girls set to benefit from vaccine against cervical cancer. http://www.gavi.org/library/news/press-releases/2014/1-5-million-girls-set-To-benefit-from-vaccine-Against-cervical-cancer/(6 January 2017, date last accessed).
13. Geohive. 2015. www.geohive.com/cntry/uganda/aspx.
14. Gok M, Heideman DA, van Kemenade FJ et al. 2012. Offering self-sampling for human papillomavirus testing to non-Attendees of the cervical screening programme: characteristics of the responders. European Journal of Cancer 48: 1799-808.
15. Gold MR. 1996. Cost-effectiveness in Health and Medicine. New York: Oxford University Press.
16. Goldhaber-Fiebert JD, Stout NK, Ortendahl J et al. 2007. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Population Health Metrics 5: 11.
17. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al. 2005. Cost-effectiveness of cervical-cancer screening in five developing countries. New England Journal of Medicine 353: 2158-68.
18. Gravitt PE, Belinson JL, Salmeron J, Shah KV. 2011. Looking ahead: A case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. International Journal of Cancer 129: 517-27.
19. Herrero R, Wacholder S, Rodriguez AC et al. 2011. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A communitybased randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery 1: 408-19.
20. Jamison DT, Breman JG, Measham AR, Alleyne G et al. 2006. Disease Control Priorities in Developing Countries. 2nd edn. Washington, DC: Oxford University Press and The World Bank.
21. Jeronimo J, Bansil P, Lim J et al. 2014. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. International Journal of Gynecology Cancer 24: 576-85.
22. Kim JJ, Kuntz KM, Stout NK et al. 2007. Multiparameter calibration of a natural history model of cervical cancer. American Journal of Epidemiology 166: 137-50.
23. Kitchener HC, Castle PE, Cox JT. 2006. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 24: S3/63-70.
24. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A et al. 2011. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): A community-based randomised controlled trial. Lancet 378: 1868-73.
25. Levinson KL, Abuelo C, Chyung E et al. 2013. The Peru cervical cancer prevention study (PERCAPS): community-based participatory research in Manchay, Peru. Int J Gynecol Cancer 23: 141-7.
26. Mandigo M, Frett B, Laurent JR et al. 2015. Pairing community health workers with HPV self-sampling for cervical cancer prevention in rural Haiti. International Journal of Gynaecology and Obstetrics 128: 206-10.
27. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. 2015. Thresholds for the cost-effectiveness of interventions: Alternative approaches. Bulletin of the World Health Organization 93: 118-24.
28. Moses E, Pedersen HN, Mitchell SM et al. 2015. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial. Tropical Medicine and International Health 20: 1355-67.
29. Munoz N, Mendez F, Posso H et al. 2004. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. Journal of Infectious Diseases 190: 2077-87.
30. Mvundura M, Tsu V. 2014. Estimating the costs of cervical cancer screening in high-burden Sub-Saharan African countries. International Journal of Gynaecology and Obstetrics 126: 151-5.
31. Qiao YL, Sellors JW, Eder PS et al. 2008. A new HPV-DNA test for cervicalcancer screening in developing regions: A cross-sectional study of clinical accuracy in rural China. The Lancet Oncology 9: 929-36.
32. Rosenbaum AJ, Gage JC, Alfaro KM et al. 2014. Acceptability of selfcollected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador. International Journal of Gynaecology and Obstetrics 126: 156-60.
33. Sankaranarayanan R, Nene BM, Shastri SS et al. 2009. HPV screening for cervical cancer in rural India. New England Journal of Medicine 360: 1385-94.
34. Sankaranarayanan R, Swaminathan R, Brenner H et al. 2010. Cancer survival in Africa, Asia, and Central America: A population-based study. The Lancet Oncology 11: 165-73.
35. Santesso N, Mustafa RA, Schunemann HJ et al. 2016. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-And-Treat strategies to prevent cervical cancer. International Journal of Gynaecology and Obstetrics 132: 252-8.
36. Sauvaget C, Muwonge R, Sankaranarayanan R. 2013. Meta-Analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia. Int J Gynaecol Obstet 120: 218-223.
37. Shastri SS, Mittra I, Mishra GA et al. 2014. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. Journal of National Cancer Institute 106: dju009.
38. SossauerG, ZbindenM, Tebeu PMet al. 2014. Impact of an educational intervention on womens knowledge and acceptability of human papillomavirus selfsampling: A randomized controlled trial in Cameroon. PLoS One 9: e109788.
39. Sowjanya AP, Paul P, Vedantham H et al. 2009. Suitability of self-collected vaginal samples for cervical cancer screening in periurban villages in Andhra Pradesh, India. Cancer Epidemiology, Biomarkers and Prevention 18: 1373-8.
40. Stinnett AA, Paltiel AD. 1997. Estimating CE ratios under second-order uncertainty: The mean ratio versus the ratio of means. Medical Decision Making 17: 483-9.
41. Surveillance Epidemiology and End Results (SEER) Program. 2011.
42. SEER Stat Database: Incidence-SEER 18 Regs Research Data Hurricane Katrina Impacted Louisiana Cases Nov 2011 Sub (1973-2009 varying)-Linked to County Attributes-Total U.S., 1969-2010 Counties.
43. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R et al. 2003. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva, Switzerland: World Health Organization.
44. United Nations Department of Economic and Social Affairs, Population Division. 2013. World Population Prospects, The 2012 Revision. Geneva.
45. Verdoodt F, Jentschke M, Hillemanns P et al. 2015. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: A systematic review and meta-Analysis of randomised trials. European Journal of Cancer 51: 2375-85.
46. World Bank. 2013.World Development Indicators. Geneva: World Bank.
47. World Health Organization. 2001. Macroeconomics and health: Investing in health for economic development: Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization.
48. World Health Organization. 2010. Global Health Observatory Data Repository. http://apps.who.int/gho/data/node.main.506?lang=en (6 January 2017, date last accessed).
49. World Health Organization. 2013. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva: WHO.